eFFECTOR Therapeutics IPO

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register for Details

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is eFFECTOR Therapeutics's ticker symbol?


What is eFFECTOR Therapeutics's stock price?

0.5148 as of 9/22/23

eFFECTOR Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
8/24/2017 Series C $39.1MM raised $XXX.XX $XXX.XX
12/22/2015 Series B $56MM raised $XXX.XX $XXX.XX
5/20/2013 Series A $56.98MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about eFFECTOR Therapeutics

Forge green plus iconForge green minus icon

What is eFFECTOR Therapeutics funding to date?

eFFECTOR Therapeutics has raised $152.08MM to date.
Forge green plus iconForge green minus icon

When was eFFECTOR Therapeutics founded?

eFFECTOR Therapeutics was founded in 2012.
Updated on: Jun 12, 2022